# Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss

> **NCT02322099** · PHASE4 · TERMINATED · sponsor: **University College Dublin** · enrollment: 53 (actual)

## Conditions studied

- Bone Demineralization

## Interventions

- **DRUG:** Alendronate
- **DRUG:** Placebo
- **DIETARY_SUPPLEMENT:** calcium carbonate and colecalciferol
- **DRUG:** Tenofovir disoproxil

## Key facts

- **NCT ID:** NCT02322099
- **Lead sponsor:** University College Dublin
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05
- **Primary completion:** 2019-09
- **Final completion:** 2019-09
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** Due to the COVID-19 pandemic the study was terminated prematurely
- **Last updated:** 2022-05-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02322099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02322099, "Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02322099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*